NEWS
Making it easy for our investors to stay current with our portfolio companies and their industries.
November 21, 2024
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
November 18, 2024
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
November 13, 2024
Southeast urologist deploys AI tool, boosting cancer identification by 25%
November 13, 2024
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 8, 2024
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting